首页> 外文OA文献 >The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

【2h】

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

机译：哺乳动物催乳素抑制抑制对蛋白质阳性晚期晚期乳腺癌骨髓骨骼骨骼健康的影响，接受Everolimus和Exemestane在IIIB阶段的4EG 4

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Peyman Hadji; Oliver Stoetzer; Thomas Decker; Christian M. Kurbacher; Frederik Marmé; Andreas Schneeweiss; Christoph Mundhenke; Andrea Distelrath; Peter A. Fasching; Michael P. Lux; Diana Lüftner; Wolfgang Janni; Mathias Muth; Julia Kreuzeder; Claudia Quiering; Eva-Marie Grischke; Hans Tesch;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial [J] . Peyman Hadji, Oliver Stoetzer, Thomas Decker, Journal of Bone Oncology . 2019,第4期

机译：IIIb 4EVER期试验中，哺乳动物雷帕霉素抑制靶点对接受依维莫司加依西美坦治疗的激素受体阳性晚期乳腺癌绝经后妇女骨健康的影响
2. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial [J] . Tesch Hans, Stoetzer Oliver, Decker Thomas, International Journal of Cancer =: Journal International du Cancer . 2019,第4期

机译：Everolimus Plus Exemestane在绝经后妇女患有激素受体阳性，人体表皮生长因子受体2阴性局部晚期或转移性乳腺癌的疗效和安全性：单臂，IIIB阶段的结果的结果
3. Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part [J] . Cortes J., Martinez Janesz N., Sablin M. P., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Suppla2期

机译：BI 836845（一种胰岛素样生长因子（IGF）配体中和抗体）与依西美坦和依维莫司合用在激素受体阳性，局部晚期或转移性乳腺癌的绝经后妇女中的1b / 2期临床试验：该阶段的初步结果1b部分
4. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial [O] . Peyman Hadji, Oliver Stoetzer, Thomas Decker, 2019

机译：IIIb 4EVER期试验中哺乳动物雷帕霉素靶点抑制对接受依维莫司加依西美坦治疗的激素受体阳性晚期乳腺癌绝经后妇女骨骼健康的影响
5. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial [O] . Hans Tesch, Oliver Stoetzer, Thomas Decker, 2018

机译：Everolimus Plus Exemestan在绝经后妇女患有激素受体阳性，人表皮生长因子受体2阴性局部晚期或转移性乳腺癌的疗效和安全性：单臂，IIIB的结果结果

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

著录项

引文网络

相似文献

相关主题

期刊订阅